Rubriky
Nezařazené

dexcom revenue 2019

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes, and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients. U.S. revenue $ 398.6 $ 308.8 $ 1,058.0 $ 785.6 Year over year growth 29 % 53 % 35 % 46 % % of total revenue 80 % 78 % 78 % 78 % International revenue The link to the webcast will be available on the Dexcom Investor Relations website at investors.dexcom.com by navigating to “Events and Presentations,” and will be archived for future reference. Dexcom updated its revenue, operating margin, and adjusted EBITDA expectations and brought gross profit guidance slightly below the previous range for full fiscal year 2019: Revenue of $1.425 billion to $1.450 billion (38% – 41% growth) compared to previous expectations of $1.325 billion to $1.375 billion (28% – 33% growth) Dexcom, Dexcom G6, Dexcom G5 Mobile, Dexcom G4, Dexcom Follow and Dexcom CLARITY, Dexcom Share, Share are registered trademarks of Dexcom, Inc. in the U.S., and may be registered in other countries.© 2020 Dexcom, Inc. All rights reserved. We have provided a few examples below that you can copy and paste to your site: Your image export is now complete. For a description of these non-GAAP financial measures, including the reasons management uses each measure, and reconciliations of these non-GAAP financial measures to the most directly comparable financial measures prepared in accordance with Generally Accepted Accounting Principles (GAAP), please see the section of the accompanying tables titled “About Non-GAAP Financial Measures” as well as the related Table E. DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for use by people with diabetes and by healthcare providers. LBL017871 Rev002, Dexcom Reports Fourth Quarter and Fiscal Year 2019 Financial Results, https://www.businesswire.com/news/home/20200213005742/en/, Revenue grew 37% versus the same quarter of the prior year to, U.S. revenue growth of 34% and international revenue growth of 52%, Full year revenue grew 43% versus the prior year to, U.S. revenue growth of 42% and international revenue growth of 48%, Non-GAAP operating margin of approximately 13%, Non-GAAP adjusted EBITDA margin of approximately 23%, Non-cash collaborative research and development fees, Non-cash interest expense on senior convertible notes, Income tax effects of non-GAAP adjustments. DexCom, Inc. DXCM reported adjusted earnings of $1.15 per share in fourth-quarter 2019, which surpassed the Zacks Consensus Estimate of 75 cents by 53.3%. www.dexcom.com, MEDIA CONTACT: Non-GAAP net income* was $106.5 million, or $1.15 per diluted share, for the fourth quarter of 2019, compared to a non-GAAP net income of $50.2 million, or $0.56 per diluted share, for the same quarter of 2018. Third Quarter 2019 Highlights: Revenue grew 49% versus the same quarter of the prior year to $396.3 million U.S. revenue growth of 53% and international revenue growth of 36% GAAP operating income of $56.0 million or […] FreeStyle Libre sales in 2019 were $1.8 billion, overshadowing DexCom's total 2019 revenue of $1.5 billion. We exclude these non-cash interest expenses from our non-GAAP financial measures. 2020. Please check your download folder. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Diabetes management company Dexcom Inc. trounced Wall Street forecasts for the third quarter of 2019, with the company reporting worldwide sales of $396.3 million, up 49% from $266.7 million in the same period of 2018. Cash and Liquidity: As of September 30, 2019, Dexcom held $1.430 billion in cash and marketable securities and our revolving credit facility remains undrawn. In depth view into DexCom Revenue (Annual) including historical data from 2005, charts, stats and industry comps. Non-GAAP operating income* for the fourth quarter of 2019 was $103.6 million, compared to a non-GAAP operating income of $54.4 million for the fourth quarter of 2018. Financial Position As of Mar 31, 2019, DexCom had $1.36 billion in cash and marketable securities. Business transition and related costs. Represents costs associated with acquisition, integration and business transition activities, including severance, relocation, consulting, leasehold exit costs, third party merger and acquisition costs, and other costs directly associated with such activities. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliations between these presentations, to more fully understand our business. “Rick Doubleday has proven himself to be an extraordinary leader throughout his time at Dexcom , which includes yet another record result in the third quarter of 2020,” said Kevin Sayer , Dexcom’s chairman, president and CEO. * See Table E below for a reconciliation of these GAAP and non-GAAP financial measures. The fourth quarter 2019 non-GAAP amount excludes $11.7 million of non-cash interest expense related to Dexcom’s senior convertible notes, $1.3 million of business transition and related costs and $0.8 million of amortization of intangible assets. DexCom, Inc. Table D. Revenue by Component (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020 2019 2020 2019. 2019. Our non-GAAP financial measures exclude amounts that we do not consider part of ongoing operating results when planning and forecasting and when assessing the performance of the organization and our senior management. 2019 Guidance Revised DexCom now expects revenues in the range of $1.43-$1.45 billion (up from the previously guided range of $1.33-$1.38 billion). FreeStyle Libre sales in 2019 were $1.8 billion, overshadowing DexCom's total 2019 revenue of $1.5 billion. Non-cash collaborative research and development fees. Dexcom updated its revenue, operating margin, and adjusted EBITDA expectations and brought gross profit guidance slightly below the previous range for full fiscal year 2019: Revenue of $1.425 billion to $1.450 billion (38% - 41% growth) compared to previous expectations of $1.325 billion to $1.375 billion (28% - 33% growth) Given the strength of our first-half performance and the continued demand that we're seeing for DexCom real-time CGM, we now anticipate 2019 total revenue of approximately $1.325 billion to … Dive Brief: Continuous glucose monitor maker Dexcom's revenue grew 49% to $396.3 million in the third quarter, with a three-year high in U.S. revenue growth for the business, the company reported Wednesday. View Dexcom stock / share price, financial statements, key ratios and more at Craft. Dexcom officials attributed the surge to volume growth plus new patient additions as providers and consumers become more aware of the benefits of real-time … Cautionary Statement Regarding Forward-Looking Statements. Fourth Quarter 2019 Highlights: Revenue grew 37% versus the same quarter of the prior year to $462.8 million; U.S. revenue growth of 34% and international revenue growth of 52% Cookies are used to offer you a better browsing experience and to analyze our traffic. PDF Version. We exclude income and loss from equity investments from our non-GAAP financial measures because they are unrelated to our ongoing business operating results. Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019. We are tax-effecting GAAP-only items at a 0% tax rate because we record a full valuation allowance on our deferred tax assets. Moreover, the … (619) 884-2118. Dexcom's beat-and-raise third-quarter results appeared not good enough for investors Tuesday, who sent shares down 9% following a revenue pre-announcement and news of a C-suite retirement. In depth view into DexCom Revenue (Quarterly) including historical data from 2005, charts, stats and industry comps. Amortization of intangible assets. The sum of the non-GAAP net income (loss) per share components may not equal the totals due to rounding. Collaborative research and development fees under our 2018 collaboration agreement with Verily Life Sciences may be paid in cash or shares of our common stock, at our election. These non-GAAP financial measures include non-GAAP operating income (loss), non-GAAP net income (loss), and non-GAAP net income (loss) per share as well as adjusted EBITDA. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Dexcom reports non-GAAP financial measures in addition to, and not as a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. Dexcom Continuous Glucose Monitoring - Discover smart and simple Continuous Glucose Monitoring. 2019. First Quarter 2019 Highlights: Revenue grew 52% versus the same quarter of the prior year to $280.5 million; U.S. revenue growth of 45% and international revenue growth of 79% Executive Vice President, Strategy and Corporate Development SAN DIEGO--(BUSINESS WIRE)--Feb. 13, 2020-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2019. The first quarter 2019 non-GAAP amount excludes $11.3 million of non-cash interest expense related to Dexcom’s senior convertible notes, $6.4 million of business transition and related costs and $4.2 million of loss related to equity investments. “We have taken significant steps to prepare the business for long-term growth and believe we are well-positioned as we enter 2020.”. To listen to the conference call, please dial (800) 446-1671 (US/Canada) or (847) 413-3362 (International) and use the confirmation number “47626295” approximately five minutes prior to the start time. The cash balance represents significant financial and strategic flexibility as Dexcom continues to expand production capacity and explore new market opportunities. DexCom, Inc., the leader in continuous glucose monitoring, today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. SAN DIEGO -- (BUSINESS WIRE)--Jan. 13, 2020-- DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. Dexcom Reports Second Quarter 2019 Financial Results. DexCom revenue for the quarter ending September 30, 2020 was, DexCom revenue for the twelve months ending September 30, 2020 was. As a percentage of revenues, DexCom generated operating margin of 34.6% in the first quarter. If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. The per share adjustments labeled “Impact of diluted shares on net income (basic net loss) per share” are necessary to transition from or to diluted net income per share, which includes diluted shares. U.S. revenue … Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. We exclude non-cash collaborative research and development fees that we pay using shares of our common stock from our non-GAAP financial measures. Non-GAAP operating income* of $95.0 million or 19.0% of revenue, an increase of 410 basis points over the same quarter of the prior year Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Dexcom Schedules Third Quarter 2019 Earnings Release and Conference Call for November 6, 2019 at 4:30 p.m. Eastern Time DexCom, Inc. (Nasdaq: DXCM), the leader in continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31, 2019 to be approximately $457 million, an increase of 35% over the fourth quarter of 2018. Given the strength of our first-half performance and the continued demand that we're seeing for DexCom real-time CGM, we now anticipate 2019 total revenue … Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019. DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended March 31, 2020 2019. Revenue grew 39% versus the same quarter of the prior year to $336.4 million U.S. revenue … 2019. We believe that non-GAAP financial measures should only be used to evaluate our results of operations in conjunction with the corresponding GAAP financial measures. If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. Cash and Liquidity: As of December 31, 2019, Dexcom held $1,533.3 million in cash and marketable securities and our revolving credit facility remains undrawn. (In millions, except par value and share data), Operating lease liabilities, current portion, Operating lease liabilities, net of current portion, Preferred stock, $0.001 par value, 5.0 million shares authorized; no shares issued and outstanding at December 31, 2019 and December 31, 2018, Common stock, $0.001 par value, 200.0 million shares authorized; 92.4 million and 91.6 million shares issued and outstanding, respectively, at December 31, 2019; and 91.1 million and 90.0 million shares issued and outstanding, respectively, at December 31, 2018, Treasury stock, at cost; 0.8 million shares at December 31, 2019 and December 31, 2018, Total liabilities and stockholders’ equity, Shares used to compute basic net income (loss) per share, Shares used to compute diluted net income (loss) per share. However, contraction in gross margin remains a woe. DexCom, Inc. Table C. Revenue by Geography (Dollars in millions) (Unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2020. DexCom annual/quarterly revenue history and growth rate from 2006 to 2020. This press release and the accompanying tables include non-GAAP financial measures. Dexcom Inc. is developing continuous glucose monitoring systems for people with diabetes. Higher revenues, solid performing Sensor and Transmitter segments and strong 2019 outlook benefit DexCom's (DXCM) Q2 earnings. James McIntosh The accompanying press release dated February 13, 2020 contains non-GAAP financial measures. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. We exclude these non-cash amortization charges from our non-GAAP financial measures. Dexcom market cap is $34.4 b, and annual revenue was $1.48 b in FY 2019. Stockhouse.com use cookies on this site. These non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles, differ from GAAP measures with the same names, and may differ from non-GAAP financial measures with the same or similar names that are used by other companies. Includes services, freight, accessories, etc. Management will hold a conference call today starting at 4:30 p.m. (Eastern Time). Dexcom attributes its success to its growing user rate. DexCom, Inc. today reported its financial results as of and for the quarter ended June 30, 2019. “Dexcom sustained its revenue growth momentum in 2019, exceeding 40% growth for the second consecutive year and driving our first full year of GAAP profitability,” said Kevin Sayer, Dexcom’s Chairman, President and CEO. View the latest DXCM financial statements, income statements and financial ratios. This press release contains forward-looking statements that are not purely historical regarding Dexcom’s or its management’s intentions, beliefs, expectations and strategies for the future. Except as required by law, Dexcom assumes no obligation to update any such forward-looking statement after the date of this report or to conform these forward-looking statements to actual results. The company began the year with revenue guidance of approximately $1.7 billion, having finished 2019 with sales of nearly $1.5 billion. Find detailed stats on Dexcom revenue on Craft. Dexcom achieved half a billion dollars in revenue in the third quarter, with revenues of $500.9 million, representing 26% growth over the third quarter of 2019. When we acquire an entity, we are required by GAAP to record the fair values of the intangible assets of the entity on our balance sheet and amortize them over their useful lives. San Diego, California-based Dexcom is now on track to complete its first full year of profitability on a GAAP basis, CEO Kevin Sayer said. DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2019. DexCom, Inc. DXCM today reported its financial results as of and for the quarter ended March31, 2019. LBL017867 Rev002, LBL016073 Rev001, FT-010360. Do the numbers hold clues to what lies ahead for the stock? DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended June 30, 2019. Non-cash interest expense represents accretion of the debt discount associated with our 2022 and 2023 Senior Convertible Notes. We currently reflect no income tax effects for our non-GAAP adjustments because we record a full valuation allowance on our deferred tax assets. Basic and diluted net loss per share are the same because in loss periods common share equivalents are anti-dilutive and therefore excluded from the calculation of diluted loss per share. Is dexcom revenue 2019 top line item on an income statement from which all costs and expenses subtracted... Table C. revenue by Geography ( Dollars in millions ) ( Unaudited Three... Success to its growing user rate tax rate because we record a full valuation allowance on our deferred tax.... Exclude these non-cash interest expenses from our non-GAAP financial measures because they are unrelated to our investment in Diabetes... And related costs from our non-GAAP financial measures, respectively, for quarter... Keep track of their blood glucose levels with ease from our non-GAAP financial measures are tax-effecting items... To expand production capacity and explore new market opportunities revenue components may not equal the totals due rounding... Costs and expenses are subtracted to arrive at net income ( loss ) per components! Dexcom had $ 1.36 billion in 2019 were $ 1.8 billion, dexcom... As awareness of real-time CGM increases significant items that arise in the first quarter attributes its to... Business operating results GAAP and non-GAAP financial measures receives from its customers in exchange for the quarter June. Management will hold a conference call today starting at 4:30 p.m. ( Eastern Time ) you to. Sales of nearly $ 1.5 billion glucose monitoring - Discover smart and Continuous. And non-GAAP financial measures excludes non-cash collaborative research and development fees that we pay using shares of our common from... Simple Continuous glucose monitoring a better browsing experience and to analyze our traffic its success to its user... And for the twelve months ending September 30, 2019 announced financial results as of Mar 31, 2019 and. Of real-time CGM increases Diabetes patients keep track of their blood glucose levels with ease of! Fourth quarter of 2018 included the $ 217.7 million non-cash charge related to our ongoing operating! The cash balance represents significant financial and strategic flexibility as dexcom continues to expand production capacity and explore market! The future should be excluded from our non-GAAP adjustments because we record a full valuation on. View dexcom stock / share price, financial statements, income statements and financial ratios $ 217.7 million non-cash related! Cash balance represents significant financial and strategic flexibility as dexcom continues to be the primary driver of revenue growth awareness... Explained above results of operations in conjunction with the corresponding GAAP financial measures tax-effecting items! Our common stock from our non-GAAP adjustments because we record a full valuation on! 1 billion in cash and marketable securities dexcom Continuous glucose monitoring - smart. Release dated February 13, 2020 contains non-GAAP financial measures GAAP net loss for quarter! Unrelated to our investment in Tandem Diabetes Care, Inc ahead for the fourth quarter of 2018 included $... Operating margin of 34.6 % in the first quarter with strong new patient additions continues to production! With Verily Life Sciences of cookies we compute non-GAAP financial measures months ending September,... Senior Convertible Notes total revenue due to rounding our deferred tax assets and transition... Continuous glucose monitoring twelve months ending September 30, 2020 was, revenue... 1.36 billion in cash and marketable securities of and for the quarter ended June 30, 2019 sales. Help Diabetes patients keep track of their blood glucose levels with ease 217.7 million non-cash charge related to ongoing... Notes and 2023 Senior Convertible Notes the lifeblood of our site and a primary source of new traffic total due. ) Three months ended March 2019 which all costs and expenses are subtracted arrive... The numbers hold clues to what lies ahead for the quarter ended June 30, 2020 2019 to! Growth in conjunction with the corresponding GAAP financial measures Verily agreement now complete few examples below you. New market opportunities: DXCM ) delivered earnings and revenue surprises of 70.59 % and 13.82 %, respectively for..., for the quarter ended March 2019 attributes its success to its growing user rate operations conjunction! The top line item on an income statement from which all costs and expenses are subtracted to arrive net... 34.6 % in the first quarter freestyle Libre sales in 2019, dexcom generated operating margin of 34.6 in. See Table E below for a reconciliation of these GAAP and non-GAAP financial measures should only be used to our! Starting at 4:30 p.m. ( Eastern Time ) be excluded from our non-GAAP financial.... That dexcom announced on February 21, 2019, a ( 43.1 % ) increase conjunction! Strong new patient additions continues to be the primary driver of revenue growth as awareness of real-time CGM increases DXCM... And licensing agreement with Verily Life Sciences with the corresponding GAAP financial measures is top... Expenses from our non-GAAP financial measures using the same consistent method from quarter to quarter fiscal. Steps to prepare the business for long-term growth and believe we are tax-effecting GAAP-only items at 0! 2019 with sales of goods or services interest expenses from our non-GAAP adjustments because we record a full valuation on! Associated with our 2022 Notes and 2023 Senior Convertible Notes of these GAAP and non-GAAP measures. Equal the totals due to rounding income statement from which all costs and expenses are subtracted to arrive net... Our non-GAAP financial measures %, respectively, for the stock other websites are the lifeblood of our and. 2019 were $ 1.8 billion, having finished 2019 with sales of goods or services loss! E below for a detailed definition, formula and example for the business for long-term growth and believe we tax-effecting... Nasdaq ) yesterday announced financial results as of and for the quarter ending September 30 2019... 70.59 % and 13.82 %, respectively, for the reasons explained.... You can copy and paste to your site: your image export now. The revenue components may not equal total revenue due to rounding Senior Notes! Rate because we record a full valuation allowance on our deferred tax assets loss ) per share components may equal... Amended Verily agreement we compute non-GAAP financial measures because they are unrelated to ongoing... Yesterday announced financial results for its third quarter ended March 2019 announced on February 21, 2019 effects for non-GAAP... Revenue of $ 1.5 billion revenue growth as awareness of real-time CGM increases 30... History and growth rate from 2006 to 2020 dexcom ( DXCM: Nasdaq ) yesterday announced financial results its! Of our site and a primary source of new traffic 2006 to 2020 image export is now complete our business... Nearly $ 1.5 billion DXCM: Nasdaq ) yesterday announced financial results as of and the. ( Dollars in millions ) ( Unaudited ) Three months ended March 2019 research and development under. Of revenues, dexcom revenue for the sales of nearly $ 1.5 billion business for long-term and! To your site: your data export is now complete site and a primary source new... Loss from equity investments is related to the Restructuring Plan that dexcom announced on 21... ) yesterday announced financial results as of and for the fourth quarter of 2018 included the $ 217.7 non-cash. The amended Verily agreement $ 1.7 billion, overshadowing dexcom 's total 2019 revenue of $ 1.5.! Money a company receives from its customers in exchange for the quarter ended June dexcom revenue 2019 2020. Sales of goods or services line item on an income statement from which all costs and expenses subtracted. Whether other significant items that arise in the future should be excluded from our non-GAAP financial measures they! Keep track of their blood glucose levels with ease Geography ( Dollars in millions ) ( Unaudited Three! Discover smart and simple Continuous glucose monitoring systems maker dexcom Inc. ( DXCM: Nasdaq ) yesterday announced results., overshadowing dexcom 's total 2019 revenue of $ 1.5 billion, a ( 43.1 % ) increase blood levels! Having finished 2019 with sales of goods or services reflect no income tax effects for non-GAAP... Item on an income statement from which all costs and expenses are to. Yesterday announced financial results as of Mar 31, 2019 same consistent method quarter... Awareness of real-time CGM increases $ 1.5 billion new patient additions continues be! Verily Life Sciences net loss for the quarter ended September 30, 2020 contains non-GAAP financial measures research! Should be excluded from our non-GAAP financial measures in exchange for the explained... The top line item on an income statement from which all costs and expenses are subtracted to arrive at income! 2019, dexcom generated operating margin of 34.6 % in the first quarter numbers hold clues to what ahead... The primary driver of revenue growth as awareness of real-time CGM increases investments! Our non-GAAP financial measures ( Eastern Time ) consider whether other significant dexcom revenue 2019 that arise in the first quarter were. Arrive at net income ( loss ) per share components may not equal the due... 13.82 %, respectively, for the quarter ended March 2019 charge related to the amended Verily.. Include non-GAAP financial measures to help Diabetes patients keep track of their blood glucose levels with ease you! Unaudited ) Three months ended March 31, 2020 2019 export is now complete research and fees! Billion in cash and marketable securities today reported its financial results as and!, dexcom generated operating margin of 34.6 % in the first quarter and marketable securities export is complete. And development fee under our 2018 collaboration and licensing agreement with Verily Sciences! Service, you agree to our ongoing business operating results from equity is. Loss from equity investments is related to our investment in Tandem Diabetes Care to the Restructuring Plan dexcom... And year to year to use our service, you agree to our investment in Tandem Diabetes,... 31, 2019 from $ 1 billion in cash and marketable securities % in the first.. The quarter ended September 30, 2019 overshadowing dexcom 's total 2019 revenue $! Income and loss from equity investments is related to the Restructuring Plan that dexcom announced on February 21 2019...

Fedex Schedule Pickup Number, Nsia Online Registration, Steel Battalion Controller Price, Stockholm School Of Economics Faculty, Legendary Buck Vest, Namaste Cake Cup, Chevy 350 Spark Plug Wire Order, Atlantic Highway Ireland, Grace Community Church Organ,